Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Purdue Pharma L p
Purdue Pharma L p_20100107
Purdue Pharma L p_20100128

Purdue Pharma L p patents


Recent patent applications related to Purdue Pharma L p. Purdue Pharma L p is listed as an Agent/Assignee. Note: Purdue Pharma L p may have other listings under different names/spellings. We're not affiliated with Purdue Pharma L p, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Purdue Pharma L p-related inventors


 new patent  Dosage form containing oxycodone and naloxone

The present invention concerns a dosage form comprising oxycodone and naloxone which is characterized by specific in vivo parameters such as tmax, Cmax, AUCt value, mean bowel function score and/or duration of analgesic efficacy.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent

an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.... Purdue Pharma L p

Tamper resistant dosage forms

Tamper resistant controlled release formulations.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Oxycodone formulations

The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C24/Cmax oxycodone ratio of 0.6 to 1.0 or 0.7 to 1 after oral administration at steady state to patients and methods thereof... Purdue Pharma L p

Methods and compositions for decreasing gastric emptying

Disclosed in certain embodiments is a method of decreasing gastric emptying comprising administering to a subject an effective amount of a sodium-channel blocker to decrease gastric emptying.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Mhc-i restricted epitopes containing non-natural amino acid residues

The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein... Purdue Pharma L p

Crystalline forms of tyrosine kinase inhibitors and their salts

The disclosure relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzoate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.... Purdue Pharma L p

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

Tamper resistant pharmaceutical formulations

Disclosed in certain embodiments is a solid oral dosage form comprising a heat-labile gelling agent; a thermal stabilizer; and a drug susceptible to abuse.... Purdue Pharma L p

Pyrimidines as sodium channel blockers

The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of... Purdue Pharma L p

Benzomorphan analogs and the use thereof

In one aspect, the invention provides compounds of Formula (I) or (II): (I) or (II) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2a, R2b, R3, R4, Z and G are defined as set forth in the disclosure. The invention also provides compounds of Formulae A and B and... Purdue Pharma L p

Dibenzazepine derivatives and use thereof

and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or... Purdue Pharma L p

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

Acetaminophen-containing analgesic formulations with reduced hepatotoxicity

An analgesic composition is provided which is safe and effective to patients requiring pain modulation. The analgesic composition contains (a) acetaminophen and (b) at least three components chosen from (i) a bioavailable oral opioid; (ii) a non-steroidal anti-inflammatory drug; (iii) a sulfur-containing, N-acetyl-p-benzoquinone imine scavenging agent or prodrug thereof; or... Purdue Pharma L p

Matrix for sustained, invariant and independent release of active compounds

The invention concerns a storage stable pharmaceutical formulation comprising preferably two active compounds in a non-swellable diffusion matrix, whereby the compounds are released from the matrix in a sustained, invariant and, if several compounds are present, independent manner and the matrix is determined with respect to its substantial release characteristics... Purdue Pharma L p

Methods for making 3-o-protected morphinones and 3-o-protected morphinone dienol carboxylates

Also disclosed are methods for making 3-O-protected morphine dienol carboxylates comprising allowing a compound of formula (I) to oxidize in the presence of a chlorine-containing compound and a compound of formula R1SR2; and allowing the product of the oxidation step to react with an acylating agent... Purdue Pharma L p

Transdermal therapeutic system for administering the active substance buprenorphine

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the... Purdue Pharma L p

Tamper resistant pharmaceutical formulations

Disclosed in certain embodiments is a solid oral dosage form comprising a plurality of particles, each particle comprising (i) a core comprising an active agent susceptible to abuse and an internal adhesion promoter, wherein the cores are (i) dispersed in a matrix comprising a controlled release material or (ii) coated... Purdue Pharma L p

Pyrimidine carboxamides as sodium channel blockers

The present disclosure provides substituted pyrimidine carboxamides of Formula (I) and the pharmaceutically acceptable salts and solvates thereof wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula... Purdue Pharma L p

7-beta-alkyl analogs of orvinols

The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R1a, R1b, R1c, X, Y, Z, G, O, W1 and W2 are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I), and... Purdue Pharma L p

Spirocyclic morphinans and use thereof

In one aspect, the invention provides compounds of Formula I: (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, Y, Za are defined as set forth in the disclosure. The invention also provides compounds of any one of Formulae II to VII, IA to IC,... Purdue Pharma L p

06/29/17 / #20170183337

Trpv1 antagonists including dihydroxy substituent and uses thereof

and pharmaceutically acceptable derivatives thereof, where R1, R4, R8, R9, and m are as defined herein, compositions comprising an effective amount of a Compound of Formula (I) or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, pain associated with osteoarthritis, osteoarthritis, UI,... Purdue Pharma L p

06/22/17 / #20170173000

Pharmaceutical formulation containing irritant

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.... Purdue Pharma L p

06/08/17 / #20170157062

Buprenorphine-wafer for drug substitution therapy

The present invention relates to oral pharmaceutical dosage forms comprising buprenorphine with the dosage form releasing buprenorphine instantly upon oral, preferably sublingual, application of the dosage form. The present invention also relates to the use of such dosage forms for treating pain in a human or animal or for drug... Purdue Pharma L p

06/08/17 / #20170157114

Abuse resistant opioid transdermal delivery device containing opioid antagonist microspheres

The present invention provides abuse-resistant transdermal delivery devices containing an opioid agonist intended for analgesic purposes in pain patients.... Purdue Pharma L p

06/08/17 / #20170157115

Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic, an opioid antagonist and one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the... Purdue Pharma L p

06/01/17 / #20170151229

Methods of manufacturing oral formulations

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Purdue Pharma L p

05/25/17 / #20170143697

Methods of providing analgesia

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the... Purdue Pharma L p

05/18/17 / #20170135959

Tamper resistant dosage form comprising co-extruded, adverse agent particles and process of making same

The present invention relates to co-extruded pharmaceutical compositions and dosage forms comprising an adverse agent, such as an opioid antagonist, which can be sequestered. The pharmaceutical compositions and dosage forms diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to... Purdue Pharma L p

05/18/17 / #20170136005

Methods of treating opiate dependency and preventing non-oral opiate abuse among opiate addicts

The present invention relates to the use of an inseparable combination of morphine and at least one opiate antagonist with a bioavailability of less than 5% on oral administration for producing a medicament to be administered orally for treatment of opiate dependency in humans and to the use of an... Purdue Pharma L p

05/18/17 / #20170136006

Methods of manufacturing oral dosage forms

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the... Purdue Pharma L p

05/11/17 / #20170128369

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128370

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128371

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128372

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128373

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128374

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128375

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/11/17 / #20170128384

Buprenorphine transdermal delivery system

A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount... Purdue Pharma L p

05/11/17 / #20170128440

Tamper resistant dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

05/04/17 / #20170119685

Tamper resistant oral opioid agonist formulations

Oral dosage forms containing an opioid antagonist in a sequestered form are described. The opioid antagonist is sequestered such that it is not released or substantially not released in the gastrointestinal tract from the dosage form which is administered orally intact. However, when the dosage form is chewed, crushed, heated... Purdue Pharma L p

05/04/17 / #20170119756

Pharmaceutical formulation containing irritant

Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.... Purdue Pharma L p

04/27/17 / #20170112765

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

04/27/17 / #20170112828

Pharmaceutical preparation containing oxycodone and naloxone

The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.... Purdue Pharma L p

04/20/17 / #20170105990

Crystalline forms of tyrosine kinase inhibitors and their salts

The invention relates to various polymorphic forms and amorphous form of sodium 4-((3-(4-cyclohexylpiperazin-1-yl)-6-oxo-6H-anthra[1,9-cd]isoxazol-5-yl)amino)benzate, including the polymorphic form A, mixtures of the polymorphs, process for the preparation thereof and the use thereof in a pharmaceutical composition containing thereof.... Purdue Pharma L p

04/20/17 / #20170107220

Azamorphinan derivatives and use thereof

The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, Y, and Z are defined as set forth in the specification. The invention is also directed to use of compounds of any one of Formulae I-VIII, and the pharmaceutically... Purdue Pharma L p

04/13/17 / #20170100337

Naltrexone hydrochloride compositions

The present invention relates to compositions and methods of stabilizing naltrexone hydrochloride.... Purdue Pharma L p

04/06/17 / #20170096421

Carboxamide derivatives and use thereof

and the pharmaceutically acceptable salts and solvates thereof, wherein Z, HET, R10, and E are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I-A to treat a disorder responsive to the blockade of sodium channels. Compounds of the... Purdue Pharma L p

03/30/17 / #20170087151

Controlled release hydrocodone formulations

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Purdue Pharma L p

03/30/17 / #20170087152

Methods of providing analgesia

A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.... Purdue Pharma L p

03/30/17 / #20170087153

Controlled release hydrocodone formulations

A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the... Purdue Pharma L p

Patent Packs
03/23/17 / #20170079923

Alcohol resistant dosage forms

Opioid controlled release formulation resistant to alcohol extraction of the opioid.... Purdue Pharma L p

03/16/17 / #20170073313

Benzomorphan analogs and use thereof

The invention provides compounds as represented by Formula I or I′ and pharmaceutically acceptable salts, solvates, and diastereomers thereof: Wherein R1, R2, R2a, R3, and R4 are defined in the disclosure. The invention also provides compounds of Formulae II, III, and A-H, and pharmaceutically acceptable salts, solvates, and diastereomers thereof.... Purdue Pharma L p

03/09/17 / #20170065524

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

03/09/17 / #20170065525

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

03/09/17 / #20170065527

Pharmaceutical dosage forms

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.... Purdue Pharma L p

03/02/17 / #20170056393

Method of providing sustained analgesia with buprenorphine

A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at... Purdue Pharma L p

03/02/17 / #20170057942

Isoquinoline derivatives and use thereof

The Invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, N-oxides, or diastereomers thereof: wherein W1, W2, W3, J1, J2, A, R1, R2, R3, R4, R5, a, and b are defined as set forth in the specification. The Invention also provides uses of the compounds of any... Purdue Pharma L p

02/23/17 / #20170049713

Transdermal delivery system comprising buprenorphine

The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an... Purdue Pharma L p

02/09/17 / #20170037046

10-substituted morphinan hydantoins

The application is directed to compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein R1-R9, Y, Z are defined as set forth in the specification. The invention is also directed to use of compounds of Formula (I) and the maceutically acceptable salts and solvates thereof to treat... Purdue Pharma L p

01/26/17 / #20170020820

Tamper resistant solid oral dosage forms

Disclosed in certain embodiments is a solid oral dosage form comprising: (a) an inert tamper resistant core; and (b) a coating surrounding the core, the coating comprising an active agent.... Purdue Pharma L p

01/26/17 / #20170020863

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

01/26/17 / #20170020864

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected... Purdue Pharma L p

01/26/17 / #20170020865

Opioid agonist/opioid antagonist/acetaminophen combinations

The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered... Purdue Pharma L p

01/19/17 / #20170014405

Abuse-resistant controlled-release opioid dosage form

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Purdue Pharma L p

01/19/17 / #20170014406

Abuse-resistant controlled-release opioid dosage form

Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as... Purdue Pharma L p

Patent Packs
01/12/17 / #20170008882

Pyridines and pyrimidines and use thereof

The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W1, W2, W3, and R5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and... Purdue Pharma L p

01/05/17 / #20170001986

Indazoles and use thereof

In one aspect, the present disclosure provides indazoles of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R3, R4, R5, R6, Z1, Z2, Z3, and G are defined as set forth in the specification. Further, the present disclosure also provides compounds of Formulae II and IA,... Purdue Pharma L p

01/05/17 / #20170001969







ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Purdue Pharma L p in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Purdue Pharma L p with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###